Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency

Blood

Volumn 114, Issue 19, 2009, Pages 4089-4098

  Borte, Stephan ^a   Pan Hammarström, Qiang ^b   Liu, Chonghai ^b   Sack, Ulrich ^a   Borte, Michael ^c   Wagner, Ulf ^a   Graf, Dagmar ^d   Hammarström, Lennart ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Klinikum St Georg   (Germany)

^d Reising Ackermann Human Genetic Laboratory   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; SYNDECAN 1;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 77249109584     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-207423     Document Type: Article

References (57)

1. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497-502.
2. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34-48.
3. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-286.
4. Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031-1036.
5. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101(4):435-439.
6. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162-166.
7. Sewell WA, Buckland M, Jolles SR. Therapeutic strategies in common variable immunodeficiency. Drugs. 2003;63(13):1359-1371.
8. Brière F, Bridon JM, Chevet D, et al. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J Clin Invest. 1994;94(1):97-104.
9. Marconi M, Plebani A, Avanzini MA, et al. IL-10 and IL-4 co-operate to normalize in vitro IgA production in IgA-deficient (IgAD) patients. Clin Exp Immunol. 1998;112(3):528-532.
10. Asano T, Kaneko H, Terada T, et al. Molecular analysis of B-cell differentiation in selective or partial IgA deficiency. Clin Exp Immunol. 2004;136(2):284-290.
11. Hummelshoj L, Ryder LP, Nielsen LK, Nielsen CH, Poulsen LK. Class switch recombination in selective IgA-deficient subjects. Clin Exp Immunol. 2006;144(3):458-466.
12. Zielen S, Bauscher P, Hofmann D, Meuer SC. Interleukin 10 and immune restoration in common variable immunodeficiency. Lancet. 1993;342-(8873):750- 751.
13. Kelley SK, Gelzleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol. 2006;148(8):1116-1123.
14. Rosenblum IY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol. 2002;35(1):56-71.
15. Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin Immunol Immunopathol. 1992;64(1):46-56.
16. Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2. N Engl J Med. 1994;331(14):918-921.
17. Cunningham-Rundles C, Kazbay K, Zhou Z, Mayer L. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J Interferon Cytokine Res. 1995;15(3):269-276.
18. Cunningham-Rundles C, Bodian C, Ochs HD, et al. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol. 2001;100(2):181-190.
19. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57-63.
20. Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196(7):969-977.
21. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
22. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol. 2004;173(1):657-665.
23. Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol. 2005;175(12):7867-7879.
24. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002;298(5598):1630-1634.
25. Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002;16(4):559-569.
26. Wood N, Bourque K, Donaldson DD, et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol. 2004;231(1-2):133-145.
27. European Society for Immunodeficiencies (ESID). Diagnostic criteria for PID. http://www.esid.org/workingparty.php?party=3&sub=-2&id73. Accessed August 16, 2009.
28. + cells in cryo-preserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods. 2003;278(1-2):79-93.
29. Schlesier M, Warnatz K. Characterization of B-lymphocytes. In: Sack U, Tárnok A, Rothe G, eds. Cellular Diagnostics: Basics, Methods and Clinical Applications of Flow Cytometry. Basel, Switzerland: Karger, 2009:211-229.
30. Salzer U, Neumann C, Thiel J, et al. Screening of functional and positional candidate genes in families with common variable immunodeficiency. BMC Immunol. 2008;9:3.
31. + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. J Clin Immunol. 2006;26(2):113-125.
32. Berglund LJ, Wong SW, Fulcher DA. B-cell maturation defects in common variable immunodeficiency and association with clinical features. Pathology. 2008;40(3):288-294.
33. Taubenheim N, von Hornung M, Durandy A, et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J Immunol. 2005;175(8):5498-5503.
34. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820-828.
35. Sekine H, Ferreira RC, Pan-Hammarström Q, et al. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A. 2007;104(17):7193-7198.
36. Vodjgani M, Aghamohammadi A, Samadi M, et al. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J Investig Allergol Clin Immunol. 2007;17(5):321-328.
37. Avery DT, Ellyard JI, Mackay F, et al. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol. 2005;174(7):4034-4042.
38. Arce S, Luger E, Muehlinghaus G, et al. CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol. 2004;75(6):1022-1028.
39. Di Noia J, Neuberger MS. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature. 2002;419(6902):43- 48.
40. Kinoshita K, Harigai M, Fagarasan S, Muramatsu M, Honjo T. A hallmark of active class switch recombination: transcripts directed by I promoters on looped-out circular DNAs. Proc Natl Acad Sci U S A. 2001;98(22):12620-12623.
41. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol. 2006;177(8):5236-5247.
42. Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol. 2007;179(12):8180-8190.
43. Konforte D, Paige CJ. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol. 2006;177(12):8381-8392.
44. Ortiz J, Fernández-Arquero M, Urcelay E, et al. Interleukin-10 polymorphisms in Spanish IgA deficiency patients: a case-control and family study. BMC Med Genet. 2006;7:56.
45. Pons J, Ferrer JM, Martínez-Pomar N, Iglesias-Alzueta J, Matamoros N. Costimulatory molecules and cytokine production by T lymphocytes in common variable immunodeficiency disease. Scand J Immunol. 2006;63(5):383-389.
46. Oliva A, Scala E, Quinti I, et al. IL-10 production and CD40L expression in patients with common variable immunodeficiency. Scand J Immunol. 1997;46(1):86-90.
47. Fritsch A, Junker U, Vogelsang H, Jager L. On interleukins 4, 6 and 10 and their interrelationship with immunoglobulins G and M in common variable immunodeficiency. Cell Biol Int. 1994;18(11):1067-1075.
48. Ravanbakhsh M, Sarafnejad A, Aghamohammadi A, et al. CD40 ligand expression on stimulated T-helper lymphocytes in patients with common variable immunodeficiency. Iran J Allergy Asthma Immunol. 2007;6(3):129-135.
49. Isgrò A, Marziali M, Mezzaroma I, et al. Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency. J Immunol. 2005;174(8):5074-5081.
50. Tsuruoka N, Arima M, Arguni E, et al. Bcl6 is required for the IL-4-mediated rescue of the B cells from apoptosis induced by IL-21. Immunol Lett. 2007;110(2):145-151.
51. Györy I, Minarovits J. Epigenetic regulation of lymphoid specific gene sets. Biochem Cell Biol. 2005;83(3):286-295.
52. Muegge K, Young H, Ruscetti F, Mikovits J. Epigenetic control during lymphoid development and immune responses: aberrant regulation, viruses, and cancer. Ann N Y Acad Sci. 2003;983:55-70.
53. Green MR, Yoon H, Boss JM. Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility. J Immunol. 2006;177(6):3865-3873.
54. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, et al. Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol. 2006;72(9):1114-1131.
55. Caprioli F, Sarra M, Caruso R, et al. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol. 2008;180(3):1800-1807.
56. Strengell M, Lehtonen A, Matikainen S, Julkunen I. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol. 2006;79(6):1279-1285.
57. Saito T, Kitayama D, Sakamoto A, et al. Effective collaboration between IL-4 and IL-21 on B cell activation. Immunobiology. 2008;213(7):545-555.